FY2025 EPS Estimates for BioNTech Reduced by HC Wainwright

BioNTech SE Sponsored ADR (NASDAQ:BNTX) – Investment analysts at HC Wainwright decreased their FY2025 earnings estimates for BioNTech in a report issued on Wednesday, December 10th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($4.65) per share for the year, down from their previous estimate of ($4.62). HC Wainwright has a “Buy” rating and a $140.00 price target on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($3.88) per share. HC Wainwright also issued estimates for BioNTech’s Q4 2025 earnings at ($0.63) EPS, Q1 2026 earnings at ($2.27) EPS, Q2 2026 earnings at ($2.29) EPS and FY2026 earnings at ($3.63) EPS.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.75 by ($0.89). BioNTech had a negative net margin of 17.91% and a negative return on equity of 3.03%. The business had revenue of $1.78 billion for the quarter, compared to analysts’ expectations of $1.21 billion. During the same quarter in the prior year, the company posted $0.81 earnings per share. The firm’s quarterly revenue was up 22.0% compared to the same quarter last year.

Other equities analysts also recently issued research reports about the company. Jefferies Financial Group reissued a “buy” rating and set a $151.00 target price on shares of BioNTech in a research report on Wednesday, December 3rd. UBS Group upgraded shares of BioNTech to a “hold” rating in a report on Thursday, December 4th. Cowen reissued a “hold” rating on shares of BioNTech in a research report on Monday, November 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a research report on Tuesday, October 14th. Finally, Bank of America decreased their price target on BioNTech from $134.00 to $130.00 and set a “buy” rating for the company in a research note on Wednesday, October 22nd. Ten investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, BioNTech has a consensus rating of “Moderate Buy” and a consensus target price of $137.75.

BioNTech Trading Down 1.1%

Shares of BNTX stock opened at $93.81 on Monday. The company has a market cap of $21.12 billion, a PE ratio of -35.67 and a beta of 1.30. BioNTech has a 1 year low of $81.20 and a 1 year high of $129.27. The stock’s 50 day simple moving average is $102.04 and its two-hundred day simple moving average is $105.05. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.12 and a quick ratio of 7.02.

Institutional Investors Weigh In On BioNTech

Several large investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. raised its stake in BioNTech by 30.0% in the first quarter. Charles Schwab Investment Management Inc. now owns 243,468 shares of the company’s stock worth $22,170,000 after buying an additional 56,113 shares in the last quarter. Invesco Ltd. increased its holdings in shares of BioNTech by 643.7% in the 1st quarter. Invesco Ltd. now owns 645,142 shares of the company’s stock valued at $58,747,000 after acquiring an additional 558,389 shares during the period. HighTower Advisors LLC raised its position in shares of BioNTech by 46.2% in the 1st quarter. HighTower Advisors LLC now owns 16,077 shares of the company’s stock worth $1,464,000 after acquiring an additional 5,079 shares in the last quarter. Groupama Asset Managment raised its position in shares of BioNTech by 126.6% in the 1st quarter. Groupama Asset Managment now owns 196,544 shares of the company’s stock worth $18,662,000 after acquiring an additional 109,819 shares in the last quarter. Finally, Banco Bilbao Vizcaya Argentaria S.A. lifted its stake in shares of BioNTech by 7.1% during the 1st quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 7,467 shares of the company’s stock worth $664,000 after purchasing an additional 498 shares during the last quarter. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.